References
- Ministero della Salute. Vaccinazione contro il Papillomavirus umano. [cited 2018 Oct 22]. Available from: http://www.salute.gov.it/portale/salute/p1_5.jsp?lingua=italiano&id=31&area=Vaccinazioni
- Perez S, Zimet GD, Tatar O, et al. Human papillomavirus vaccines: successes and future challenges. Drugs. 2018 Sep;78(14):1385–1396. PubMed PMID: 30269207.
- AGENZIA ITALIANA DEL FARMACO. DETERMINAZIONE 28 febbraio 2007. [cited 2018 Oct 22]. http://www.epicentro.iss.it/problemi/hpv/pdf/gardasil_GU.pdf
- Piano Nazionale Prevenzione Vaccinale PNPV 2017-2019. [cited 2018 Jun 4]. Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf
- Infezioni da hpv e cervicocarcinoma. [cited 2018 Oct 22]. Available from: http://www.epicentro.iss.it/problemi/hpv/aggiornamenti.asp
- Scavone C, Rafaniello C, Brusco S, et al. Did the New Italian law on mandatory vaccines affect adverse event following immunization‘s reporting? A pharmacovigilance study in Southern Italy. Front Pharmacol. 2018 Sep 4;9:1003.
- Scavone C, Sessa M, Clementi E, et al. Italian immunization goals: a political or scientific heated debate? Front Pharmacol. 2018 May;30(9):574.
- Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). [cited 2018 Oct 22]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6305a1.htm.
- Chandler RE, Juhlin K, Fransson J, et al. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase(®). Drug Saf. 2017 Jan;40(1):81–90.
- Schurink-Van‘t Klooster TM, Kemmeren JM, van der Maas NAT, et al. No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls. Vaccine. 2018 Sep 19. pii: S0264-410X(18)31268-4. DOI:10.1016/j.vaccine.2018.09.019
- Butts BN, Fischer PR, Mack KJ. Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature. J Child Neurol. 2017 Oct;32(11):956–965. .
- HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. [cited 2018 Nov 10] Available from: https://www.ema.europa.eu/documents/referral/hpv-vaccines-article-20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-pots_en.pdf
- Sessa M, Rafaniello C, Sportiello L, et al. Campania Region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. Expert Opin Drug Saf. 2016 Dec;15(sup2)):9–15.
- Mascolo A, Scavone C, Sessa M, et al. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacol Res. 2017Sep;123:122–129.
- Sessa M, Rossi C, Mascolo A, et al. Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance. Expert Opin Drug Saf. 2015;14(9):1341–1351.
- Tafuri S, Fortunato F, Gallone MS, et al. Systematic causality assessment of adverse events following HPV vaccines: analysis of current data from Apulia region (Italy). Vaccine. 2018 Feb 14;36(8):1072–1077. .
- Rapporto sulla sorveglianza postmarketing dei vaccini in Italia. Anno 2012. [cited 2018 Nov 2]. Available from: http://www.aifa.gov.it/sites/default/files/Rapporto_sulla_sorveglianza_postmarketing_dei_vaccin_%20in_Italia_Anno_2012.pdf
- DELIBERAZIONE DEL DIRETTORE GENERALE N. 343 del 10/04/2018. [cited 2018 Nov 9]. Available from: http://www.istitutotumori.na.it/IstitutoPascale/PubblicazioneFtp/2018/Allegati/126250.pdf.
- DETERMINAZIONE DEL DIRETTORE GENERALE n. 27 DEL 14 FEBBRAIO 2017. [cited 2018 Nov 9]. Available from: https://www.soresa.it/amministrazionetrasparente/AmministrazioneTrasparente/Provvedimenti/Provvedimenti%20dirigenti/Determinazioni/2017/Determina%20n.%2027%20del%2014%20Febbraio%202017.pdf.
- Andamento della campagna vaccinale contro l’Hpv nella Asl di Napoli. [cited 2018 Nov 9]. Available from: http://www.epicentro.iss.it/territorio/campania/pdf/HPV_Napoli1_301012.pdf
- Liu XC, Bell CA, Simmonds KA, et al. Adverse events following HPV vaccination, Alberta 2006-2014. Vaccine. 2016 Apr 4;34(15):1800–1805. .
- De Vincenzo R, Conte C, Ricci C, et al. Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health. 2014;6:999–1010. Published 2014 Dec 3.
- Hung CF, Ma B, Monie A, et al. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther. 2008;8(4):421–439.
- Schneider K, Grønhøj C, Hahn CH, et al. Therapeutic human papillomavirus vaccines in head and neck cancer: a systematic review of current clinical trials. Vaccine. 2018;36(45):6594–6605. .
- Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5(05):F123–F138.
- Salvadori MI. Human papillomavirus vaccine for children and adolescents. Paediatr Child Health. 2018 June 12;23(4):262–265.
- Albazaz R, Wong YT, Homer-Vanniasinkam S. Complex regional pain syndrome: a review. Ann Vasc Surg. 2008 Mar;22(2):297–306. .
- Agarwal AK, Garg R, Ritch A, et al. Postural orthostatic tachycardia syndrome. Postgrad Med J. 2007 Jul;83(981):478–480. Review.
- Avellaneda Fernández A, Pérez Martín A, Izquierdo Martínez M, et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009 Oct 23;9(Suppl 1):S1. .
- Setiawan D, Luttjeboer J, Pouwels KB, et al. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis. Jpn J Clin Oncol. 2017 Mar 1;47(3):265–276.
- Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): an interplay among drugs, viruses, and immune system. Int J Mol Sci. 2017 Jun 9;18(6). pii: E1243.
- Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4(7):e39. Published 2015 Jul 17.
- Scavone C, Sportiello L, Sullo MG, et al. Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania Region (Italy): BIO-cam observational study. Front Pharmacol. 2017;8:607. .
- Feiring B, Laake I, Bakken IJ, et al. HPV vaccination and risk of chronic fatigue syndrome/myalgiac encephalomyelitis: a nationwide register-based study from Norway. Vaccine. 2017 Jul 24;35(33):4203–4212. .
- Awong IE, Dandurand KR, Keeys CA, et al. Drug-associated Guillain-Barré syndrome: a literature review. Ann Pharmacother. 1996 Feb;30(2):173–180.
- Arnheim-Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906. .
- Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012 Feb;271(2):193–203.
- Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014 Apr;275(4):398–408.
- Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine. 2017 Mar 23;35(13):1729–1732. .
- European Medicine Agency. [cited 2018 Nov 10]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/pharmacovigilance/legal-framework
- Rapporto sulla sorveglianza postmarketing dei vaccini in Italia 2014-2015. [cited 2018 May 29]. Available from: http://www.aifa.gov.it/sites/default/files/Rapporto_sorveglianza_vaccini_2014-2015acc.pdf.
- Rapporto sulla sorveglianza postmarketing dei vaccini in Italia 2016. [cited 2018 May 29] Available from: http://www.aifa.gov.it/sites/default/files/Rapporto_Vaccini_2016.pdf.
- Rapporto sulla sorveglianza postmarketing dei vaccini in Italia 2009-2010. [cited 2018 Oct 25] Available from: http://www.aifa.gov.it/sites/default/files/Rapporto_sulla_sorveglianza_postmarketing_dei_vaccini_%20in_Italia_Anno_2009-2010.pdf
- Lu B, Kumar A, Castellsagué X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011 Jan 12;11:13.
- Arana JE, Harrington T, Cano M, et al. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine. 2018 Mar 20;36(13):1781–1788. .
- Gonçalves AK, Cobucci RN, Rodrigues HM, et al. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014 Nov-Dec;18(6):651–659.
- Edwards IR. Spontaneous reporting–of what? Clinical concerns about drugs. Br J Clin Pharmacol. 1999;48(2):138–141.
- Pal SN, Duncombe C, Falzon D, et al. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75–81.
- Ferrajolo C, Capuano A, Trifirò G, et al. Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001–2012. Expert Opin Drug Saf. 2014 Sep;13(Suppl 1):S9–S20.
- Carnovale C, Raschi E, Leonardi L, et al. No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. Expert Rev Vaccines. 2018 Apr;17(4):363–381.
- Auricchio F, Scavone C, Cimmaruta D, et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. 2017 Dec;16(12):1359–1371.
- Cimmaruta D, Maiorino MI, Scavone C, et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opin Drug Saf. 2016 Dec;15(sup2):77–83.